Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 10/20 | 0.81 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.62 |
| ▸ | FLT3 | P36888 | 2/20 | 0.62 |
| ▸ | CDK1 | P06493 | 1/20 | 0.62 |
| ▸ | CDK4 | P11802 | 1/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.60 |
| ▸ | SYK | P43405 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | BTK | Q06187 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29574737 | 1.00 | ULK1 (0.81) | ULK1CHEK1FLT3CDK1CDK4 | |
| SCHEMBL17544668 | 1.00 | ULK1 (0.81) | ULK1CHEK1FLT3CDK1CDK4 | |
| SCHEMBL17544886 | 0.90 | ULK1 (0.85) | ULK1CHEK1FLT3CDK1SYK | |
| SCHEMBL29575010 | 0.90 | ULK1 (0.94) | ULK1CHEK1FLT3CDK1CDK4 | |
| SCHEMBL17545130 | 0.90 | ULK1 (0.94) | ULK1CHEK1FLT3CDK1CDK4 | |
| SCHEMBL17547458 | 0.89 | ULK1 (1.00) | ULK1CHEK1FLT3CDK1CDK4 | |
| SCHEMBL17547456 | 0.85 | ULK1 (1.00) | ULK1CHEK1FLT3CDK1SYK | |
| SCHEMBL29575372 | 0.85 | ULK1 (1.00) | ULK1CHEK1FLT3CDK1SYK | |
| SCHEMBL29575449 | 0.85 | ULK1 (1.00) | ULK1CHEK1FLT3CDK1SYK | |
| SCHEMBL17545008 | 0.85 | ULK1 (1.00) | ULK1CHEK1FLT3CDK1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-09-19 | — | — | US | disclosed |
| US-20190248806-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-08-15 | — | — | US | disclosed |
| US-20190152989-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-05-23 | — | — | US | disclosed |
| US-10266549-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3185868-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033100-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033100-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689397-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | ULK1 1/4885CHEK1 62/4885FLT3 1127/4885 |
| US-10266549-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | ULK1 1/4885CHEK1 62/4885FLT3 1127/4885 |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | ULK1 1/4885CHEK1 71/4885FLT3 1303/4885 |
| US-20190248806-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | ULK1 1/4885CHEK1 71/4885FLT3 1303/4885 |
| US-20190152989-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | ULK1 1/4885CHEK1 71/4885FLT3 1303/4885 |
| US-10774092-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | ULK1 1/4885CHEK1 62/4885FLT3 1127/4885 |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | ULK1 1/4885CHEK1 71/4885FLT3 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.